Nicotine treatment of mild cognitive impairment
A 6-month double-blind pilot clinical trial
Make Comment
See Comments
Share
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
- Editor's Note from Richard Kryscio, Associate Editor of Biostatistics:
- Richard J. Kryscio, Lexington, KYkryscio@uky.edu
Submitted April 04, 2012 - Reply from the authors
- Paul A. Newhouse, Director, Center for Cognitive Medicine, Vanderbilt University Medical Centerpaul.newhouse@vanderbilt.edu
- Diantha Howard, University of Vermont
Submitted February 09, 2012 - Control over type I error in this study??
- Michael Gold, Chief Medical Officer, Allon Therapeuticsmgold@allontherapeutics.com
Submitted February 07, 2012
You May Also be Interested in
- ArticleTemporal Cognitive and Brain Changes in Korsakoff SyndromeAngéline Maillard, Alice Laniepce, Nicolas Cabé, et al.February 26, 2021
- ArticleLong-term Effects of Cholinesterase Inhibitors on Cognitive Decline and MortalityHong Xu, Sara Garcia-Ptacek, Linus Jönsson, et al.March 19, 2021
- WriteClick: Editor's ChoiceNicotine Treatment of Mild Cognitive Impairment: a 6-Month Double-Blind Pilot Clinical TrialAuthor ResponseEditor's Note from Associate Editor of BiostatisticsMichael Gold, Paul A. Newhouse, Richard J. Kryscio, et al.June 04, 2012
- ArticleVitamin D, smoking, EBV, and long-term cognitive performance in MS11-year follow-up of BENEFITMarianna Cortese, Kassandra L. Munger, Elena H. Martínez-Lapiscina, et al.April 16, 2020
- ArticleApathy rating scores and β-amyloidopathy in patients with Parkinson disease at risk for cognitive declineZhi Zhou, Martijn L.T.M. Müller, Prabesh Kanel, et al.November 15, 2019